Goldman Sachs·2026-10-27CompanyBuy$280Johnson & Johnson (JNJ.US): Management Meeting at ESMO Frames Bullish Near-Term and Longer-Term Outlook
Goldman Sachs·2026-10-26CompanyBuy$280Johnson & Johnson (JNJ.US): At ESMO, Impressive First-in-Class Prostate Cancer Data Draws Attention and OrigAMI-4 Clears the Bar
J.P. Morgan·2026-10-25CompanyNeutral$285Johnson & Johnson (JNJ.US): Encouraging Riptac (Prostate) And Rybrevant (H&N) Data Out Of ESMO
Bernstein·2026-10-14CompanyMarket-Perform$261 → $270▲Johnson & Johnson (JNJ.US) 3Q26: Bullish outlook; but FY27 EPS reset
Bernstein·2026-10-09ThematicGlobal Biopharma Mid-sized molecules: The new frontier for biopharma and CDMOs